Video

Giora Sharf Discusses Intentional, Unintentional Nonadherence in CML Patients

Although there is a clear link between nonadherence and outcomes of a patient with chronic myelogenous leukemia (CML), some patient intentionally stop taking their medication, said Giora Sharf, co-founder of the CML Advocates Network.

Although there is a clear link between nonadherence and outcomes of a patient with chronic myelogenous leukemia (CML), some patient intentionally stop taking their medication, said Giora Sharf, co-founder of the CML Advocates Network.

Some patients are unintentionally not adhering to their medication, sometimes because they simply forget, which the CML Advocates Network hopes combat through its new app.

However, there are times patients choose intentional nonadherence, often because the patient does not want to suffer from the side effects of the medication. Another dangerous barrier is when a patient feels fine, and stops treatment because he or she doesn’t see the point in taking it, Mr Sharf explained.

Related Videos
Irina Dralyuk
Edgardo S. Santos, MD, FACP, FASCO
Irina Dralyuk
Keith Ferdinand, MD, professor of medicine and the Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine
Robin Glasco, Spencer Stuart
Edgardo S. Santos, MD, FACP, FASCO
Tiago Biachi, MD, PhD
Don M. Benson, MD, PhD, James Cancer Hospital
Edgardo S. Santos, MD, FACP, FASCO
Firas El Chaer, MD, smiling during a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo